Peter Powchik Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Peter Powchik.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Peter Powchik. Peter Powchik is SVP Clin Devel & Reg Affairs in REGENERON PHARMACEUTICALS INC ($REGN) and SVP Clinical Development in REGENERON PHARMACEUTICALS INC ($REGN) and SVP Clinical Development & Reg in REGENERON PHARMACEUTICALS INC ($REGN) and SVP, Clinical Development in REGENERON PHARMACEUTICALS INC ($REGN).
Latest Insider Trading Transactions of Peter Powchik
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Dec 19 2016 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | A | 381.92 | 5,000 | 1,909,600 | 5,000 | |
Dec 19 2016 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Gift | G | 0.00 | 2,459 | 0 | 2,459 | 0 to 2.5 K |
Dec 19 2016 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Gift | G | 0.00 | 2,459 | 0 | 2,459 | 0 to 2.5 K |
Dec 19 2016 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Gift | G | 0.00 | 2,459 | 0 | 0 | 2.5 K to 0 (-100.00 %) |
Dec 19 2016 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Gift | G | 0.00 | 2,459 | 0 | 2,459 | 4.9 K to 2.5 K (-50.00 %) |
Dec 18 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | A | 555.67 | 25,000 | 13,891,750 | 25,000 | |
Dec 18 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 52.03 | 1,921 | 99,950 | 0 | |
Dec 18 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 52.03 | 1,921 | 99,950 | 17,742 | 15.8 K to 17.7 K (+12.14 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 270.43 | 10,000 | 2,704,300 | 30,000 | |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 179.13 | 14,625 | 2,619,776 | 29,250 | |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 52.03 | 8,000 | 416,240 | 6,079 | |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 52.03 | 23,000 | 1,196,690 | 14,079 | |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 30.63 | 4,736 | 145,064 | 0 | |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 578.63 | 1,500 | 867,945 | 15,821 | 17.3 K to 15.8 K (-8.66 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 577.75 | 2,258 | 1,304,560 | 17,321 | 19.6 K to 17.3 K (-11.53 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 576.65 | 2,004 | 1,155,607 | 19,579 | 21.6 K to 19.6 K (-9.29 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 575.47 | 700 | 402,829 | 21,583 | 22.3 K to 21.6 K (-3.14 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 574.75 | 900 | 517,275 | 22,283 | 23.2 K to 22.3 K (-3.88 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 573.64 | 2,717 | 1,558,580 | 23,183 | 25.9 K to 23.2 K (-10.49 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 572.60 | 2,800 | 1,603,280 | 25,900 | 28.7 K to 25.9 K (-9.76 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 571.54 | 5,598 | 3,199,481 | 28,700 | 34.3 K to 28.7 K (-16.32 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 570.63 | 3,603 | 2,055,980 | 34,298 | 37.9 K to 34.3 K (-9.51 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 569.63 | 1,405 | 800,330 | 37,901 | 39.3 K to 37.9 K (-3.57 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 2,146 | 1,243,285 | 39,306 | 41.5 K to 39.3 K (-5.18 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 250 | 144,838 | 41,452 | 41.7 K to 41.5 K (-0.60 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 30.63 | 4,736 | 145,064 | 41,702 | 37 K to 41.7 K (+12.81 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 3,755 | 2,175,459 | 36,966 | 40.7 K to 37 K (-9.22 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 718 | 415,973 | 40,721 | 41.4 K to 40.7 K (-1.73 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 52.03 | 8,000 | 416,240 | 41,439 | 33.4 K to 41.4 K (+23.92 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 10,795 | 6,254,083 | 33,439 | 44.2 K to 33.4 K (-24.40 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 2,065 | 1,196,358 | 44,234 | 46.3 K to 44.2 K (-4.46 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 52.03 | 23,000 | 1,196,690 | 46,299 | 23.3 K to 46.3 K (+98.72 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 5,210 | 3,018,414 | 23,299 | 28.5 K to 23.3 K (-18.27 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 4,521 | 2,619,241 | 28,509 | 33 K to 28.5 K (-13.69 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 179.13 | 14,625 | 2,619,776 | 33,030 | 18.4 K to 33 K (+79.46 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 2,749 | 1,592,633 | 18,405 | 21.2 K to 18.4 K (-13.00 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 4,667 | 2,703,826 | 21,154 | 25.8 K to 21.2 K (-18.07 %) |
Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 270.43 | 10,000 | 2,704,300 | 25,821 | 15.8 K to 25.8 K (+63.21 %) |
Jan 05 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 52.03 | 25,000 | 1,300,750 | 37,079 | |
Jan 05 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 418.40 | 300 | 125,520 | 10,711 | 11 K to 10.7 K (-2.72 %) |
Jan 05 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 417.44 | 1,000 | 417,440 | 11,011 | 12 K to 11 K (-8.33 %) |
Jan 05 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 416.75 | 900 | 375,075 | 12,011 | 12.9 K to 12 K (-6.97 %) |
Jan 05 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 415.20 | 1,642 | 681,758 | 12,911 | 14.6 K to 12.9 K (-11.28 %) |
Jan 05 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 414.07 | 2,758 | 1,142,005 | 14,553 | 17.3 K to 14.6 K (-15.93 %) |
Jan 05 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 412.81 | 1,700 | 701,777 | 17,311 | 19 K to 17.3 K (-8.94 %) |
Jan 05 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 411.99 | 1,122 | 462,253 | 19,011 | 20.1 K to 19 K (-5.57 %) |
Jan 05 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 410.99 | 1,400 | 575,386 | 20,133 | 21.5 K to 20.1 K (-6.50 %) |
Jan 05 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 412.78 | 11,027 | 4,551,725 | 21,533 | 32.6 K to 21.5 K (-33.87 %) |
Jan 05 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 412.78 | 3,151 | 1,300,670 | 32,560 | 35.7 K to 32.6 K (-8.82 %) |
Jan 05 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 52.03 | 25,000 | 1,300,750 | 35,711 | 10.7 K to 35.7 K (+233.40 %) |
Dec 22 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 30.63 | 3,264 | 99,976 | 0 | |
Dec 22 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 30.63 | 3,264 | 99,976 | 10,711 | 7.4 K to 10.7 K (+43.83 %) |
Dec 18 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | A | 399.66 | 34,000 | 13,588,440 | 34,000 | |
Dec 18 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | A | 52.03 | 48,000 | 2,497,440 | 62,079 | |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 30.63 | 48,000 | 1,470,240 | 4,736 | |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 277.50 | 100 | 27,750 | 25,447 | 25.5 K to 25.4 K (-0.39 %) |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 276.75 | 1,296 | 358,668 | 25,547 | 26.8 K to 25.5 K (-4.83 %) |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 276.04 | 6,893 | 1,902,744 | 26,843 | 33.7 K to 26.8 K (-20.43 %) |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 274.69 | 3,777 | 1,037,504 | 33,736 | 37.5 K to 33.7 K (-10.07 %) |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 273.77 | 5,602 | 1,533,660 | 37,513 | 43.1 K to 37.5 K (-12.99 %) |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 272.88 | 3,000 | 818,640 | 43,115 | 46.1 K to 43.1 K (-6.51 %) |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 276.09 | 22,007 | 6,075,913 | 46,115 | 68.1 K to 46.1 K (-32.31 %) |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 276.09 | 5,325 | 1,470,179 | 68,122 | 73.4 K to 68.1 K (-7.25 %) |
Jan 03 2014 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 30.63 | 48,000 | 1,470,240 | 73,447 | 25.4 K to 73.4 K (+188.63 %) |
Dec 26 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 21.25 | 4,705 | 99,981 | 0 | |
Dec 26 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 21.25 | 4,705 | 99,981 | 25,447 | 20.7 K to 25.4 K (+22.68 %) |
Dec 20 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 21.25 | 295 | 6,269 | 0 | |
Dec 20 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 271.09 | 133 | 36,055 | 20,742 | 20.9 K to 20.7 K (-0.64 %) |
Dec 20 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 264.86 | 139 | 36,816 | 20,875 | 21 K to 20.9 K (-0.66 %) |
Dec 20 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 264.86 | 23 | 6,092 | 21,014 | 21 K to 21 K (-0.11 %) |
Dec 20 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 21.25 | 295 | 6,269 | 21,037 | 20.7 K to 21 K (+1.42 %) |
Dec 20 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 270.20 | 9,000 | 2,431,800 | 20,742 | 29.7 K to 20.7 K (-30.26 %) |
Dec 17 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | A | 270.43 | 40,000 | 10,817,200 | 40,000 | |
Dec 17 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 179.13 | 14,625 | 2,619,776 | 43,875 | |
Dec 17 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 52.03 | 8,000 | 416,240 | 14,079 | |
Dec 17 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 30.63 | 8,000 | 245,040 | 52,736 | |
Dec 17 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | A | 30.63 | 48,000 | 1,470,240 | 60,736 | |
Dec 17 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 270.00 | 8 | 2,160 | 29,742 | 29.8 K to 29.7 K (-0.03 %) |
Dec 17 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 272.73 | 3,662 | 998,737 | 29,750 | 33.4 K to 29.8 K (-10.96 %) |
Dec 17 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 272.73 | 898 | 244,912 | 33,412 | 34.3 K to 33.4 K (-2.62 %) |
Dec 17 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 30.63 | 8,000 | 245,040 | 34,310 | 26.3 K to 34.3 K (+30.41 %) |
Dec 17 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 272.73 | 2,588 | 705,825 | 26,310 | 28.9 K to 26.3 K (-8.96 %) |
Dec 17 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 272.73 | 9,605 | 2,619,572 | 28,898 | 38.5 K to 28.9 K (-24.95 %) |
Dec 17 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 179.13 | 14,625 | 2,619,776 | 38,503 | 23.9 K to 38.5 K (+61.25 %) |
Dec 17 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 272.73 | 3,338 | 910,373 | 23,878 | 27.2 K to 23.9 K (-12.26 %) |
Dec 17 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 272.73 | 1,526 | 416,186 | 27,216 | 28.7 K to 27.2 K (-5.31 %) |
Dec 17 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 52.03 | 8,000 | 416,240 | 28,742 | 20.7 K to 28.7 K (+38.57 %) |
Jan 10 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Option Exercise | M | 21.25 | 752 | 15,980 | 4,705 | |
Jan 10 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Option Exercise | M | 16.80 | 5,000 | 84,000 | 0 | |
Jan 10 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Buy | M | 16.80 | 5,000 | 84,000 | 20,742 | 15.7 K to 20.7 K (+31.76 %) |
Jan 10 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Buy | M | 21.25 | 752 | 15,980 | 15,742 | 15 K to 15.7 K (+5.02 %) |
Jan 04 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Option Exercise | M | 21.25 | 30,000 | 637,500 | 295 | |
Jan 04 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Sell | S | 183.10 | 4,300 | 787,330 | 14,990 | 19.3 K to 15 K (-22.29 %) |
Jan 04 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Sell | S | 182.29 | 2,300 | 419,267 | 19,290 | 21.6 K to 19.3 K (-10.65 %) |
Jan 04 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Sell | S | 181.51 | 6,200 | 1,125,362 | 21,590 | 27.8 K to 21.6 K (-22.31 %) |
Jan 04 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Sell | S | 180.83 | 786 | 142,132 | 27,790 | 28.6 K to 27.8 K (-2.75 %) |
Jan 04 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Payment of Exercise | F | 177.82 | 12,830 | 2,281,431 | 28,576 | 41.4 K to 28.6 K (-30.99 %) |
Jan 04 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Payment of Exercise | F | 177.82 | 3,584 | 637,307 | 41,406 | 45 K to 41.4 K (-7.97 %) |
Jan 04 2013 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Buy | M | 21.25 | 30,000 | 637,500 | 44,990 | 15 K to 45 K (+200.13 %) |
Dec 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Option Exercise | M | 52.03 | 8,000 | 416,240 | 22,079 | |
Dec 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Option Exercise | M | 30.63 | 16,000 | 490,080 | 12,736 | |
Dec 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Option Exercise | M | 21.25 | 14,248 | 302,770 | 30,295 | |
Dec 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Sell | S | 171.11 | 2,000 | 342,220 | 14,990 | 17 K to 15 K (-11.77 %) |
Dec 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Sell | S | 170.44 | 4,623 | 787,944 | 16,990 | 21.6 K to 17 K (-21.39 %) |
Dec 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Sell | S | 183.13 | 500 | 91,565 | 21,613 | 22.1 K to 21.6 K (-2.26 %) |
Dec 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Sell | S | 181.25 | 100 | 18,125 | 22,113 | 22.2 K to 22.1 K (-0.45 %) |
Dec 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Sell | S | 180.62 | 1,256 | 226,859 | 22,213 | 23.5 K to 22.2 K (-5.35 %) |
Dec 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Sell | S | 179.56 | 1,000 | 179,560 | 23,469 | 24.5 K to 23.5 K (-4.09 %) |
Dec 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Sell | S | 178.33 | 2,200 | 392,326 | 24,469 | 26.7 K to 24.5 K (-8.25 %) |
Dec 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Sell | S | 177.52 | 4,266 | 757,300 | 26,669 | 30.9 K to 26.7 K (-13.79 %) |
Dec 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Sell | S | 176.79 | 1,034 | 182,801 | 30,935 | 32 K to 30.9 K (-3.23 %) |
Dec 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Payment of Exercise | F | 178.62 | 5,783 | 1,032,959 | 31,969 | 37.8 K to 32 K (-15.32 %) |
Dec 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Payment of Exercise | F | 178.62 | 1,694 | 302,582 | 37,752 | 39.4 K to 37.8 K (-4.29 %) |
Dec 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Buy | M | 21.25 | 14,248 | 302,770 | 39,446 | 25.2 K to 39.4 K (+56.54 %) |
Dec 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Payment of Exercise | F | 178.62 | 6,107 | 1,090,832 | 25,198 | 31.3 K to 25.2 K (-19.51 %) |
Dec 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Payment of Exercise | F | 178.62 | 2,743 | 489,955 | 31,305 | 34 K to 31.3 K (-8.06 %) |
Dec 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Buy | M | 30.63 | 16,000 | 490,080 | 34,048 | 18 K to 34 K (+88.65 %) |
Dec 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Payment of Exercise | F | 178.62 | 2,612 | 466,555 | 18,048 | 20.7 K to 18 K (-12.64 %) |
Dec 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Payment of Exercise | F | 178.62 | 2,330 | 416,185 | 20,660 | 23 K to 20.7 K (-10.13 %) |
Dec 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Buy | M | 52.03 | 8,000 | 416,240 | 22,990 | 15 K to 23 K (+53.37 %) |
Dec 17 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Option Exercise | A | 179.13 | 58,500 | 10,479,105 | 58,500 | |
Dec 17 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clin Devel & Re ... | Option Exercise | A | 21.25 | 30,000 | 637,500 | 44,543 | |
Nov 09 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 139.05 | 900 | 125,145 | 14,990 | 15.9 K to 15 K (-5.66 %) |
Nov 09 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 138.59 | 14,244 | 1,974,076 | 15,890 | 30.1 K to 15.9 K (-47.27 %) |
Sep 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 16.80 | 15,000 | 252,000 | 0 | |
Sep 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 148.00 | 1,000 | 148,000 | 30,134 | 31.1 K to 30.1 K (-3.21 %) |
Sep 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 147.16 | 3,200 | 470,912 | 31,134 | 34.3 K to 31.1 K (-9.32 %) |
Sep 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 146.89 | 2,977 | 437,292 | 34,334 | 37.3 K to 34.3 K (-7.98 %) |
Sep 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 148.78 | 6,130 | 912,021 | 37,311 | 43.4 K to 37.3 K (-14.11 %) |
Sep 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 148.78 | 1,693 | 251,885 | 43,441 | 45.1 K to 43.4 K (-3.75 %) |
Sep 20 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 16.80 | 15,000 | 252,000 | 45,134 | 30.1 K to 45.1 K (+49.78 %) |
Aug 02 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 21.92 | 4,562 | 99,999 | 0 | |
Aug 02 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 15.64 | 10,428 | 163,094 | 0 | |
Aug 02 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 15.64 | 10,428 | 163,094 | 30,134 | 19.7 K to 30.1 K (+52.92 %) |
Aug 02 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 21.92 | 4,562 | 99,999 | 19,706 | 15.1 K to 19.7 K (+30.12 %) |
Jul 27 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 16.80 | 15,000 | 252,000 | 15,000 | |
Jul 27 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 131.07 | 2,500 | 327,675 | 15,144 | 17.6 K to 15.1 K (-14.17 %) |
Jul 27 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 130.40 | 4,519 | 589,278 | 17,644 | 22.2 K to 17.6 K (-20.39 %) |
Jul 27 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 126.76 | 5,994 | 759,799 | 22,163 | 28.2 K to 22.2 K (-21.29 %) |
Jul 27 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 126.76 | 1,987 | 251,872 | 28,157 | 30.1 K to 28.2 K (-6.59 %) |
Jul 27 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 16.80 | 15,000 | 252,000 | 30,144 | 15.1 K to 30.1 K (+99.05 %) |
Feb 23 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 21.92 | 25,438 | 557,601 | 0 | |
Feb 23 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 20.32 | 20,000 | 406,400 | 0 | |
Feb 23 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 16.80 | 15,000 | 252,000 | 30,000 | |
Feb 23 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 15.64 | 49,428 | 773,054 | 0 | |
Feb 23 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 98.05 | 1,200 | 117,660 | 15,144 | 16.3 K to 15.1 K (-7.34 %) |
Feb 23 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 97.58 | 9,600 | 936,768 | 16,344 | 25.9 K to 16.3 K (-37.00 %) |
Feb 23 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 96.45 | 23,454 | 2,262,138 | 25,944 | 49.4 K to 25.9 K (-47.48 %) |
Feb 23 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 95.46 | 10,800 | 1,030,968 | 49,398 | 60.2 K to 49.4 K (-17.94 %) |
Feb 23 2012 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 94.71 | 4,200 | 397,782 | 60,198 | 64.4 K to 60.2 K (-6.52 %) |